Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Bevacizumab in Recurrent/Refractory Non-Squamous NSCLC
NCT00411593Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2006
- Primary completion
- May 2007
- Modality
- Small Molecules, Modified Peptides
01
Overview
A Phase 2 trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Planned start Nov 2006; status: withdrawn.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00411593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00411593.